Biotech, Drugmaker | featured news

Exclusive: GSK set for Human Genome takeover

GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer.

 

Exclusive: GSK eyes replacing Human Genome board

GlaxoSmithKline Plc plans to launch a campaign to replace the entire board of Human Genome Sciences Inc with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation said on Wednesday.

 

J&J to Take Stake in Elan

J&J to Take Stake in Elan

J&J agreed to buy an 18.4% stake in Elan for $1 billion and acquire the rights to much of the Irish biotech company's research into drugs for Alzheimer's disease.

 

Subscribe to this RSS topic: Syndicate content